← Eichor
Study identifier: NCT06703034 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Characterization of the IFN-I Response in Subjects Who Experienced Severe or Mild Forms of COVID-19

Condition: COVID-19  ·  Sponsor: Hospices Civils de Lyon

PhaseNA
Planned participants134
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

Type I interferon (IFN-I) production is triggered by the detection of viral molecules, such as strands of viral RNA or DNA, by receptors known as PRRs (Pattern Recognition Receptors) present on many cell types. These interferons are secreted in minimal concentrations but can activate neighboring cells to secrete over 700 proteins with antiviral properties (inhibition of viral replication, destabilization of viral membranes, etc.). Thus, the IFN-I response serves as the immune system's first line of defense during a viral infection. Very early in the COVID-19 pandemic, several research teams, including ours, identified a defect in the type I interferon response in about one in five subjects with severe COVID-19. In-depth studies have shown that 5 to 20% of these patients with severe COVID-19 disease have genetic mutations affecting genes involved in the activation cascade of the IFN-I pathway or produce autoantibodies that neutralize IFN-I, significantly impairing the effectiveness of their IFN-I response. However, to date, not all causes of IFN-I response alteration are clearly identified, and 80% of patients suffering from severe COVID-19 do not appear to have evident genetic predispositions or anti-IFN-I autoantibodies, with the techniques currently available. This suggests the presence of other risk factors or causes that could potentially lead to alterations in the IFN-I response. The gut microbiota is recognized for its influence on host health and immunity. SARS-CoV-…

This description comes directly from the study's public registry record.

Talk to the study team

Jean-Christophe RICHARD, Pr  ·  +33472011762  ·  j-christophe.richard@chu-lyon.fr

Sophie TROUILLET-ASSANT, PhD  ·  +33472678780  ·  sophie.trouillet-assant@chu-lyon.fr

Always discuss trial participation with your own doctor first.

Locations (1)

Hospices Civils de Lyon - Hôpital de la Croix-RousseLyon, FranceRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06703034